CHICAGO, IL, (NAMC) - Biopharmaceutical company Cubist Pharmaceutical (NASDAQ: CBST) has intentions of offering $275 million of convertible subordinated notes due June 15, 2013. The company is also looking to grant the underwriters an option to purchase up to an additional $41.25 million of convertible notes.

Cubist intends to use the proceeds to redeem $165 million of its convertible subordinated notes, to increase investment in the commercialization of Cubicin, build its pipeline, and for general corporate purposes.

Goldman Sachs, Merrill Lynch and Pacific Growth Equities are co-managers on the deal.

Peter Farrell
Business News Correspondent
NAMC Newswire
www.namcnewswire.com

Click here for your free subscription to Wall Street to Main Street from the NAMC Newswire, delivered to investors daily. www.namcnewswire.com

This article can be republished either online or in print as long as credit is given to the author and the NAMC Newswire.
 
NAMC Newswire articles can now be listened to on StreetIQ.com
http://www.streetiq.com/dir/NAMC.shtml

To keep up to date with companies that we report on just register to receive the FREE Wall Street to Main Street Daily Newsletter. We feature companies that trade on the NYSE, AMEX, NASDAQ, OTCBB and Overseas, Keeping our readers informed daily. Just go to our site and register, it’s simple and free, www.namcnewswire.com/newsletter . Also be sure to visit the NAMC radio at www.namcnewswire.com/namcradio for the latest reports, interviews and corporate updates featured on the NAMC Newswire.